Table 2. Cytotoxicity of the PEGylated Gold Nanoparticles and the Platinum-Tethered Gold Nanoparticles in Colon Cancer Cell Lines HCT116, HCT15, HT29, and RKO and Human Lung Cancer Cell Line A549a.
| IC50 |
|||||
|---|---|---|---|---|---|
| platinated nanoparticles |
|||||
| cell line | PEGylated nanoparticles (nM) | wrt [Au] (nM) | wrt [Pt] (μM) | oxaliplatin control (μM) | fold increase |
| HCT116 | >10 | 2.66 ± 0.27 | 0.734 ± 0.044 | 0.728 ± 0.048 | 1.0 |
| HCT15 | >10 | 2.36 ± 0.34 | 0.652 ± 0.093 | 2.97 ± 0.21 | 4.6 |
| HT29 | >10 | 1.29 ± 0.03 | 0.357 ± 0.007 | 2.00 ± 0.15 | 5.6 |
| RKO | >10 | 0.842 ± 0.127 | 0.233 ± 0.035 | 0.295 ± 0.021 | 1.3 |
| A549 | >10 | 0.495 ± 0.062 | 0.135 ± 0.008 | 0.775 ± 0.057 | 5.7 |
a
The cytotoxicity of the platinum-tethered gold nanoparticles is given in terms of both the concentration of gold nanoparticles and as the platinum drug concentration. The fold increase is the cytotoxicity of the platinum-tethered nanoparticles (with respect to the concentration of platinum) in relation to oxaliplatin itself.